• Deutsch
    • English
  • Deutsch 
    • Deutsch
    • English
  • Einloggen
Dokumentanzeige 
  •   Startseite
  • Medizin
  • Human- und Zahnmedizin
  • Dokumentanzeige
  •   Startseite
  • Medizin
  • Human- und Zahnmedizin
  • Dokumentanzeige
JavaScript is disabled for your browser. Some features of this site may not work without it.

Effekt von Estradiol und Cimicifuga racemosa (C001) BNO1055 und deren Subfraktionen (C001/S1-S3, R1-R3) auf das Fett- und Muskelgewebe sowie auf Serumparameter der ovarektomierten Ratte

Effect of Estradiol and Cimicifuga racemosa (C001) BNO 1055 and its sub-fractions (C001/S1-S3, R1-R3) on fat and muscle tissue as well as on serumparameters of the ovariectomized rat

von Tobias Diewald
Dissertation
Datum der mündl. Prüfung:2016-11-08
Erschienen:2016-10-26
Betreuer:Prof. Dr. Wolfgang Wuttke
Gutachter:Prof. Dr. Sabine Mihm
Gutachter:Prof. Dr. Martin Oppermann
crossref-logoZum Verlinken/Zitieren: http://dx.doi.org/10.53846/goediss-5897

 

 

Dateien

Name:Doktorarbeit ediss, Tobias Diewald mit lesezeichen.pdf
Size:1.01Mb
Format:PDF
ViewOpen

Lizenzbestimmungen:


Zusammenfassung

Englisch

Climacteric complaints of postmenopausal women are often treated using hormone replacement therapy. This treatment is effective, but it is also linked to a higher risk of cardiovascular diseases or breast cancer. Research has shown that ingredients from the rhizome of Cimicifuga racemosa, CR BNO 1055, can be used to partially mitigate these complaints, too. Our study was based on two research questions. On the one hand, we wanted to assess whether the ingredients of Cimicifuga racemosa could have a beneficial effect on preventing the development of lipometabolic disorder and sarcopenia in postmenopausal women. On the other hand, we wanted to find out which of the ingredients were active ingredients and for which complaints they could be used best. To accomplish this, we divided the food extract of Cimicifuga racemosa, that had already been used in studies in our department, into fractions, each containing different ingredients. Over the course of four weeks, we fed ovariectomized rats one of the CR food fractions, an estrogenic food or a control food. Following this, we performed a quantitative computed tomography (QCT) on the rats’ hind legs to assess the development of the muscle as well as the paratibial fat depot. We were able to confirm that unlike estrogen, CR BNO 1055 neither has proliferative effects on the uterus, nor anti-proliferative effects on the heart. At the same time, none of the CR extracts were able to achieve an effect on the muscles and fatty tissues comparable to the estrogenic extract. Solely the fraction containing actein, deoxyactein and methylserotonin had a positive effect on both the increase in fatty tissue in general and the integration of fatty tissue into the muscle.
Keywords: Cimicifuga racemosa; climacteric complaints; sarcopenia; fat tissue
 

Statistik

Hier veröffentlichen

Blättern

Im gesamten BestandFakultäten & ProgrammeErscheinungsdatumAutorBetreuer & GutachterBetreuerGutachterTitelTypIn dieser FakultätErscheinungsdatumAutorBetreuer & GutachterBetreuerGutachterTitelTyp

Hilfe & Info

Publizieren auf eDissPDF erstellenVertragsbedingungenHäufige Fragen

Kontakt | Impressum | Cookie-Einwilligung | Datenschutzerklärung
eDiss - SUB Göttingen (Zentralbibliothek)
Platz der Göttinger Sieben 1
Mo - Fr 10:00 – 12:00 h


Tel.: +49 (0)551 39-27809 (allg. Fragen)
Tel.: +49 (0)551 39-28655 (Fragen zu open access/Parallelpublikationen)
ediss_AT_sub.uni-goettingen.de
[Bitte ersetzen Sie das "_AT_" durch ein "@", wenn Sie unsere E-Mail-Adressen verwenden.]
Niedersächsische Staats- und Universitätsbibliothek | Georg-August Universität
Bereichsbibliothek Medizin (Nur für Promovierende der Medizinischen Fakultät)
Robert-Koch-Str. 40
Mon – Fri 8:00 – 24:00 h
Sat - Sun 8:00 – 22:00 h
Holidays 10:00 – 20:00 h
Tel.: +49 551 39-8395 (allg. Fragen)
Tel.: +49 (0)551 39-28655 (Fragen zu open access/Parallelpublikationen)
bbmed_AT_sub.uni-goettingen.de
[Bitte ersetzen Sie das "_AT_" durch ein "@", wenn Sie unsere E-Mail-Adressen verwenden.]